Book Value per Share: revivapharma.com (RVPH)

Reviva Pharmaceuticals (RVPH) - corporate logo

The book value per share chart demonstrates the actual asset base of Reviva Pharmaceuticals (RVPH), with 1.47 serving as the current parameter value. Reviva Pharmaceuticals (RVPH) faces significant binary risk due to its focus on a single schizophrenia drug. Production is outsourced to external CDMO partners, which eliminates technical failures. The business model is scalable: patenting the development will ensure global profits with low costs.

Reviva Pharmaceuticals Holdings Inc. (RVPH) Equity per Share: for the period 07/04/2022 - 05/16/2026

revivapharma.com - analytical breakdowns and key metrics (RVPH)

- price and consensus price forecast:
Price Chart Reviva Pharmaceuticals Holdings|RVPH - Forecast Levels Chart
- market capitalization data:
Market Capitalization Reviva Pharmaceuticals Holdings, Inc.|RVPH - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Reviva Pharmaceuticals|RVPH - Accounting Capitalization|Market Capitalization to Book Value Ratio revivapharma.com|RVPH - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Reviva Pharmaceuticals|RVPH - Long-Term Debt to Capital|Short-Term Debt to Equity Reviva Pharmaceuticals Holdings, Inc.|RVPH - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Reviva Pharmaceuticals Holdings, Inc.|RVPH - Long-Term Debt|Company Short-Term Debt Reviva Pharmaceuticals
Fundamental company valuation:Reviva Pharmaceuticals Holdings, RVPH
Manufactured products of Reviva Pharmaceuticals Holdings, Inc.

Net asset value assessment is critical for Reviva Pharmaceuticals (RVPH), a biotechnology sector company developing innovative drugs for the therapy of psychiatric disorders. This metric is calculated as the difference between all company assets and liabilities divided by the number of shares, allowing investors to determine the intrinsic value of the security and assess risks via a chart of the historical book value per share.

Competitor analysis for Reviva Pharmaceuticals

Net Assets per Single Share Biogen Corp|NBIX - Share Book Value|Book Value per Share Regencell Bioscience RGC|AXSM (axsome.com) - Accounting Value of a Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|TRVI (Trevi Corp) - Net Asset Value per Share|PRAX - Net Assets per Single Share|Accounting Value of a Share anavex.com|CeriBell - Book Value per Share|Net Asset Value per Share Prothena Corporation PRTA|Accounting Value per Share Alector ALEC|Net Assets per Single Share Annexon Biosciences Inc. ANNX|Book Value per Share OMER (Omeros Corp.)|neurogene.com (NGNE) - Net Assets per Share|AC Immune SA (ACIU) - Accounting Value per Share|Voyager Therapeutics Inc (VYGR) - Net Assets per Single Share|NMRA (Neumora Therapeutics Inc) - Book Value per Share|Book Value per Share Scilex Holding Company, Inc. (SCLX)|Tevogen Bio Holdings (TVGN) - Accounting Value per Share|Accounting Value of a Share ACOG (alphacognition.com)|Cognition Therapeutics (CGTX) - Net Assets per Single Share|Share Book Value Inhibikase Therapeutics Inc IKT|Book Value per Share Cassava (SAVA)|ASRT - Accounting Value of a Share|COYA: Book Value per Share|VTGN (Vistagen) - Book Value per Share|OVID - Net Assets per Single Share|Accounting Value of a Share ABOS|Net Assets per Single Share CRVO (CervoMed Inc)|Accounting Value per Share alteritytherapeutics.com (ATHE)|Book Value per Share CLNN (Clene)|Book Value per Share PepGen Inc PEPG|JUNS: Book Value per Share|RLMD - Accounting Value per Share|Book Value per Share ANVS|Net Asset Value per Share Grace Therapeutics|AIFF (Firefly Neuroscience, Inc) - Accounting Value per Share|Book Value per Share ANEW Medical, Inc. (KLTO)|Accounting Value per Share NeuroSense Therapeutics|Book Price of a Share metaviatx.com (MTVA)|Book Value per Share NRXS|Net Assets per Share Helius Medical Technologies, Inc. HSDT|PASG: Book Value per Share|NEUP - Accounting Value per Share|NERV: Book Value per Share|ATHA (Athira Pharma Inc) - Book Value per Share|Net Assets per Single Share Addex Therapeutics, Ltd.|Net Assets per Single Share ALZN|CYCN (Cyclerion Therapeutics) - Net Assets per Single Share|Net Assets per Share PTIX (protagenic.com)|Net Assets per Single Share Pasithea Therapeutics Corp.|CRGT - Accounting Value of a Share|ATXI - Accounting Value per Share|BCLI: Net Assets per Single Share|Net Assets per Single Share Cara Therapeutics, Inc. (CARA)|chromocell.com (CHRO) - Share Book Value|ELYM - Book Value per Share|Accounting Value of a Share ITCI|Net Assets per Single Share Longboard Pharma LBPH|Equity per Share Marinus Pharma (MRNS)|NKGN: Book Value per Share|NRBO - Net Asset Value per Share|Sage Therapeutics - Accounting Value per Share|SNPX: Book Value per Share|Net Assets per Single Share Trevena, Inc TRVN|VIGL (Vigil Neuroscience, Inc.) - Accounting Value of a Share|Net Assets per Single Share WENA (Anew Medical)|Net Asset Value per Share CERE